Liver Cancer

With a wealth of drugs available for the treatment of liver cancer, one expert explained how combination therapy may be where the future is headed.

Blue Faery provides patients with hepatocellular carcinoma and their caregivers a range of focused resources. The goal of Blue Faery’s patient community is to improve the quality of life for patients, support their caregivers and give them hope, information and a voice.

The president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association discussed new initiatives and what’s on the horizon in the treatment of liver cancer.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.
 

The combination use of Abraxane plus gemcitabine and cisplatin for the treatment of advanced biliary tract cancers prolonged survival, according to phase 2 study findings.

Through community outreach, the Cholangiocarcinoma Foundation aims to increase tumor profiling and clinical trial participation.

The Food and Drug Administration approved Cyramza for certain patients with hepatocellular carcinoma.

Because of the rarity of a neuroendocrine tumor (NET) diagnosis, the Healing Net Foundation aims to educate physicians on the disease – an initiative many patient advocates feel can improve outcomes.

A Taiwanese study compares disease rates among people who used the medication daily with those who do not.